Home » Diagnostic Study Results Misrepresented by Website
Diagnostic Study Results Misrepresented by Website
Bracco Diagnostics made false and unsubstantiated claims about its diagnostic agent Isovue and omitted or minimized risks on a website that based
the claims on a clinical study, an FDA untitled letter says. The Division of Drug Marketing, Advertising and Communications cited the company for several
pages of the website that falsely indicated that the IMPACT study was a prospective trial comparing the primary endpoint of incidence of contrast-induced
nephropathy between Isovue (iopamidol) and GE Healthcare’s Visipaque (iodixanol), which are used in cardiovascular imaging. The web pages have since
been taken down, the company said.
Clinical Trials Advisor
Clinical Trials Advisor
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May